ERBB2 and breast carcinoma: In 2011, experts reached a consensus at the St Gallen International Breast Cancer Conference that breast cancer should be classified into Luminal A, Luminal B, Her-2 positive and triple negative molecular subtypes, in order to develop pertinent clinical therapeutic regimes [3].